BeiGene’s billions to support new launches, deep pipeline

By enriching its coffers with a further $2.1 billion from existing shareholders, BeiGene gains a formidable cash position as it brings to market a handful of products in the U.S. and China and advances a deep oncology pipeline -- including several programs highlighted in an investor presentation last week.

The biotech named Amgen Inc. (NASDAQ:AMGN), Baker Bros. Advisors and Hillhouse Capital as investors in the registered direct offering announced Sunday.

Read the full 698 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers